Carboplatin
- PDF / 169,199 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 86 Downloads / 115 Views
1 S
Lack of efficacy in ovarian carcinoma: case report A woman in her early 50s [exact age at the time of event onset not stated] exhibited lack of efficacy while being treated with carboplatin for ovarian serous carcinoma. The woman presented for follow-up of an advanced ovarian high grade serous carcinoma at the age of 54 years. She had been diagnosed with advanced stage IVA ovarian high grade serous carcinoma. She was a BRCA1 mutation carrier. Anamnesis showed that she had received neoadjuvant chemotherapy with 4 cycles of carboplatin [route and dosage not stated] and paclitaxel [Taxol]. This was followed by interval debulking surgery in November 2017, and she completed the chemotherapy in February 2018. The disease was determined to be resistant to carboplatin (lack of efficacy). She was then enrolled in a niraparib vs placebo clinical trial. Smith M, et al. Transient rise in CA 125 in a woman with ovarian carcinoma and COVID-19 infection. Gynecologic Oncology Reports 34: 100644, Nov 2020. Available 803517454 from: URL: http://doi.org/10.1016/j.gore.2020.100644
0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 28 Nov 2020 No. 1832
Data Loading...
